Martha L. Hyneck

693 total citations
28 papers, 546 citations indexed

About

Martha L. Hyneck is a scholar working on Pharmacology, Molecular Biology and Cancer Research. According to data from OpenAlex, Martha L. Hyneck has authored 28 papers receiving a total of 546 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 6 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in Martha L. Hyneck's work include Antibiotics Pharmacokinetics and Efficacy (5 papers), Carcinogens and Genotoxicity Assessment (3 papers) and Plant Genetic and Mutation Studies (3 papers). Martha L. Hyneck is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (5 papers), Carcinogens and Genotoxicity Assessment (3 papers) and Plant Genetic and Mutation Studies (3 papers). Martha L. Hyneck collaborates with scholars based in United States. Martha L. Hyneck's co-authors include Rosemary R. Berardi, Leslie Z. Benet, Alain Munafo, Verne A. Ray, Philip C. Smith, David E. Smith, William F. Howatt, Gordon L. Amidon, James H. Meyer and Jennifer Dressman and has published in prestigious journals such as Environmental Health Perspectives, Statistics in Medicine and Journal of Pharmaceutical Sciences.

In The Last Decade

Martha L. Hyneck

27 papers receiving 511 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martha L. Hyneck United States 14 128 113 96 93 73 28 546
G. Neugebauer Germany 19 128 1.0× 183 1.6× 156 1.6× 63 0.7× 108 1.5× 43 1.0k
D. Kadar Canada 15 130 1.0× 293 2.6× 148 1.5× 52 0.6× 125 1.7× 29 729
James M. Jaffe United States 15 192 1.5× 187 1.7× 118 1.2× 107 1.2× 91 1.2× 46 785
U. Abshagen Germany 19 165 1.3× 190 1.7× 139 1.4× 85 0.9× 95 1.3× 68 982
Pertti J. Pentikäinen Finland 18 157 1.2× 101 0.9× 74 0.8× 112 1.2× 56 0.8× 32 937
P. du Souich Canada 13 88 0.7× 109 1.0× 67 0.7× 36 0.4× 38 0.5× 31 399
E. A. Sotaniemi Finland 9 89 0.7× 204 1.8× 103 1.1× 33 0.4× 88 1.2× 15 588
S. M. Singhvi United States 12 108 0.8× 149 1.3× 118 1.2× 39 0.4× 105 1.4× 24 632
A.N. Chremos United States 18 126 1.0× 108 1.0× 173 1.8× 62 0.7× 67 0.9× 26 821
HL Elliott United Kingdom 17 186 1.5× 105 0.9× 126 1.3× 42 0.5× 65 0.9× 57 876

Countries citing papers authored by Martha L. Hyneck

Since Specialization
Citations

This map shows the geographic impact of Martha L. Hyneck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martha L. Hyneck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martha L. Hyneck more than expected).

Fields of papers citing papers by Martha L. Hyneck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martha L. Hyneck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martha L. Hyneck. The network helps show where Martha L. Hyneck may publish in the future.

Co-authorship network of co-authors of Martha L. Hyneck

This figure shows the co-authorship network connecting the top 25 collaborators of Martha L. Hyneck. A scholar is included among the top collaborators of Martha L. Hyneck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martha L. Hyneck. Martha L. Hyneck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zariffa, Névine, et al.. (2000). Case studies, practical issues and observations on population and individual bioequivalence. Statistics in Medicine. 19(20). 2811–2820. 16 indexed citations
2.
Hyneck, Martha L., et al.. (1999). Case studies, practical issues, and observations on population and individual bioequivalence. Clinical Pharmacology & Therapeutics. 65(2). 174–174. 1 indexed citations
3.
Munafo, Alain, Martha L. Hyneck, & Leslie Z. Benet. (1993). Pharmacokinetics and Irreversible Binding of Tolmetin and Its Glucuronic Acid Esters in the Elderly. Pharmacology. 47(5). 309–317. 6 indexed citations
4.
Hyneck, Martha L.. (1992). An overview of the clinical pharmacokinetics of nabumetone.. PubMed. 36. 20–4. 13 indexed citations
5.
Hyneck, Martha L., Philip C. Smith, Alain Munafo, Antony F. McDonagh, & Leslie Z. Benet. (1988). Disposition and irreversible plasma protein binding of tolmetin in humans. Clinical Pharmacology & Therapeutics. 44(1). 107–114. 70 indexed citations
6.
Cook, Jack, et al.. (1988). Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure. Clinical Pharmacology & Therapeutics. 44(5). 487–500. 33 indexed citations
7.
Hyneck, Martha L., Alain Munafo, & Leslie Z. Benet. (1988). Effect of pH on acyl migration and hydrolysis of tolmetin glucuronide.. Drug Metabolism and Disposition. 16(2). 322–324. 42 indexed citations
8.
Berardi, Rosemary R., William F. Howatt, Martha L. Hyneck, et al.. (1987). Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Digestive Diseases and Sciences. 32(5). 472–480. 96 indexed citations
9.
Hyneck, Martha L., et al.. (1987). High-performance liquid chromatographic determination of tolmetin, tolmetin glucuronide and its isomeric conjugates in plasma and urine. Journal of Chromatography B Biomedical Sciences and Applications. 420(2). 349–356. 22 indexed citations
10.
Smith, David E., Martha L. Hyneck, Rosemary R. Berardi, & Friedrich K. Port. (1985). Urinary Protein Binding, Kinetics, and Dynamics of Furosemide in Nephrotic Patients. Journal of Pharmaceutical Sciences. 74(6). 603–607. 28 indexed citations
11.
Johnson, Cary E., et al.. (1985). Cimetidine-Theophylline Interaction. Therapeutic Drug Monitoring. 7(4). 426–434. 22 indexed citations
12.
Hyneck, Martha L., et al.. (1982). Documented Effectiveness of Clinical Pharmacy Services. American Journal of Health-System Pharmacy. 39(11). 1902–1903. 7 indexed citations
13.
Mason, Nancy A., et al.. (1981). Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate. American Journal of Health-System Pharmacy. 38(10). 1449–1454. 24 indexed citations
14.
Hyneck, Martha L., Rosemary R. Berardi, & Robert M. Johnson. (1981). Interference of cephalosporins and cefoxitin with serum creatinine determination. American Journal of Health-System Pharmacy. 38(9). 1348–1352. 19 indexed citations
15.
Hyneck, Martha L., et al.. (1979). Effect of pH on the stability of heparin in 5% dextrose solutions.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 36(5). 618–21. 7 indexed citations
16.
Hyneck, Martha L., et al.. (1979). Effect of pH on the stability of heparin in 5% dextrose solutions. American Journal of Health-System Pharmacy. 36(5). 618–621. 1 indexed citations
17.
Ray, Verne A., et al.. (1974). Comparative studies of ethyl methanesulfonate-induced mutations with host-mediated, dominant lethal, and cytogenetic assays. Toxicology and Applied Pharmacology. 30(1). 107–116. 13 indexed citations
18.
Ray, Verne A., Henry E. Holden, John Ellis, & Martha L. Hyneck. (1973). A study of triflupromazine in dominant-lethal, cytogenetic and host-mediated assays. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 18(3). 301–309. 15 indexed citations
19.
Ray, Verne A. & Martha L. Hyneck. (1973). Some primary considerations in the interpretation of the dominant-lethal assay.. Environmental Health Perspectives. 6. 27–35. 21 indexed citations
20.
Ray, Verne A. & Martha L. Hyneck. (1973). Some Primary Considerations in the Interpretation of the Dominant-Lethal Assay. Environmental Health Perspectives. 6. 27–27. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by G. Neugebauer Breakdown of academic impact, for papers by D. Kadar Breakdown of academic impact, for papers by James M. Jaffe Breakdown of academic impact, for papers by U. Abshagen Breakdown of academic impact, for papers by Pertti J. Pentikäinen Breakdown of academic impact, for papers by P. du Souich Breakdown of academic impact, for papers by E. A. Sotaniemi Breakdown of academic impact, for papers by S. M. Singhvi Breakdown of academic impact, for papers by A.N. Chremos Breakdown of academic impact, for papers by HL Elliott
Rankless by CCL
2026